 Brian Montague
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prisoners | 10 | 2020 | 142 | 2.170 |
Why?
| | Prisons | 8 | 2020 | 85 | 1.570 |
Why?
| | Emergency Responders | 2 | 2022 | 37 | 1.400 |
Why?
| | HIV Infections | 20 | 2020 | 3195 | 1.260 |
Why?
| | Immunoglobulin A | 2 | 2022 | 214 | 0.810 |
Why?
| | Asymptomatic Infections | 1 | 2022 | 37 | 0.700 |
Why?
| | Viral Load | 3 | 2018 | 526 | 0.670 |
Why?
| | Antibodies, Viral | 2 | 2022 | 674 | 0.660 |
Why?
| | Continuity of Patient Care | 3 | 2018 | 297 | 0.590 |
Why?
| | Rhode Island | 10 | 2018 | 31 | 0.590 |
Why?
| | Patient Acceptance of Health Care | 3 | 2018 | 883 | 0.590 |
Why?
| | Communicable Disease Control | 2 | 2014 | 86 | 0.480 |
Why?
| | Anti-Retroviral Agents | 2 | 2016 | 251 | 0.470 |
Why?
| | Patient Identification Systems | 1 | 2015 | 16 | 0.450 |
Why?
| | Hepatitis C | 2 | 2015 | 256 | 0.450 |
Why?
| | Antiviral Agents | 3 | 2021 | 769 | 0.430 |
Why?
| | Medical Record Linkage | 1 | 2015 | 69 | 0.430 |
Why?
| | Public-Private Sector Partnerships | 1 | 2014 | 44 | 0.400 |
Why?
| | Telemedicine | 2 | 2020 | 966 | 0.390 |
Why?
| | Hepatitis B Vaccines | 1 | 2012 | 43 | 0.340 |
Why?
| | Vulnerable Populations | 2 | 2018 | 176 | 0.340 |
Why?
| | Public Health Administration | 1 | 2012 | 70 | 0.340 |
Why?
| | Hepatitis B | 1 | 2012 | 66 | 0.330 |
Why?
| | Tuberculosis | 1 | 2014 | 284 | 0.320 |
Why?
| | Health Resources | 1 | 2011 | 130 | 0.310 |
Why?
| | Vaccination | 2 | 2022 | 1428 | 0.290 |
Why?
| | Immunoglobulin G | 2 | 2022 | 892 | 0.260 |
Why?
| | Drug Industry | 1 | 2008 | 49 | 0.260 |
Why?
| | Hyperkalemia | 1 | 2008 | 36 | 0.260 |
Why?
| | Mass Screening | 6 | 2020 | 1361 | 0.250 |
Why?
| | Humans | 38 | 2024 | 145763 | 0.230 |
Why?
| | Interprofessional Relations | 1 | 2008 | 276 | 0.220 |
Why?
| | Community Health Services | 3 | 2016 | 231 | 0.220 |
Why?
| | Health Promotion | 1 | 2011 | 775 | 0.220 |
Why?
| | Electrocardiography | 1 | 2008 | 668 | 0.210 |
Why?
| | AIDS Serodiagnosis | 2 | 2014 | 23 | 0.210 |
Why?
| | Medical Informatics | 1 | 2024 | 100 | 0.200 |
Why?
| | Health Services Accessibility | 4 | 2020 | 1101 | 0.200 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.200 |
Why?
| | Meningitis | 1 | 2023 | 80 | 0.180 |
Why?
| | Masks | 1 | 2022 | 70 | 0.180 |
Why?
| | North Carolina | 3 | 2018 | 130 | 0.180 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2015 | 279 | 0.170 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 110 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 354 | 0.160 |
Why?
| | Leadership | 1 | 2024 | 402 | 0.160 |
Why?
| | Adult | 14 | 2021 | 40872 | 0.150 |
Why?
| | Teicoplanin | 1 | 2019 | 15 | 0.150 |
Why?
| | Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 3 | 0.150 |
Why?
| | Darunavir | 1 | 2019 | 20 | 0.140 |
Why?
| | Klebsiella Infections | 1 | 2019 | 26 | 0.140 |
Why?
| | Klebsiella pneumoniae | 1 | 2019 | 47 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 44 | 0.140 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 339 | 0.140 |
Why?
| | Drug Users | 2 | 2020 | 43 | 0.140 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 72 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2022 | 17325 | 0.140 |
Why?
| | beta-Lactamases | 1 | 2019 | 53 | 0.140 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 69 | 0.140 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 340 | 0.140 |
Why?
| | Quality Improvement | 3 | 2024 | 1296 | 0.140 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 912 | 0.130 |
Why?
| | Patient Dropouts | 1 | 2018 | 66 | 0.130 |
Why?
| | HIV Integrase Inhibitors | 1 | 2019 | 79 | 0.130 |
Why?
| | Male | 17 | 2021 | 73003 | 0.130 |
Why?
| | Internship and Residency | 1 | 2008 | 1269 | 0.130 |
Why?
| | Socioeconomic Factors | 3 | 2018 | 1327 | 0.130 |
Why?
| | Female | 17 | 2021 | 79035 | 0.120 |
Why?
| | Bacteremia | 1 | 2019 | 222 | 0.120 |
Why?
| | Budgets | 1 | 2015 | 14 | 0.110 |
Why?
| | Organ Transplantation | 1 | 2019 | 253 | 0.110 |
Why?
| | Biostatistics | 1 | 2015 | 19 | 0.110 |
Why?
| | State Government | 1 | 2015 | 46 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 992 | 0.110 |
Why?
| | Marijuana Use | 1 | 2019 | 222 | 0.110 |
Why?
| | Substance Abuse, Intravenous | 2 | 2014 | 127 | 0.110 |
Why?
| | Aged | 8 | 2021 | 26215 | 0.110 |
Why?
| | Confidentiality | 1 | 2015 | 80 | 0.110 |
Why?
| | Middle Aged | 10 | 2021 | 36302 | 0.110 |
Why?
| | Population Surveillance | 1 | 2018 | 484 | 0.100 |
Why?
| | Tuberculosis, Meningeal | 1 | 2014 | 7 | 0.100 |
Why?
| | Healthcare Financing | 1 | 2014 | 6 | 0.100 |
Why?
| | Drug Costs | 1 | 2015 | 117 | 0.100 |
Why?
| | Referral and Consultation | 3 | 2016 | 868 | 0.100 |
Why?
| | Tuberculin Test | 1 | 2014 | 36 | 0.100 |
Why?
| | United States | 6 | 2020 | 16123 | 0.100 |
Why?
| | Interferon-gamma Release Tests | 1 | 2014 | 32 | 0.100 |
Why?
| | Pilot Projects | 1 | 2019 | 1897 | 0.100 |
Why?
| | Incidence | 3 | 2021 | 2933 | 0.100 |
Why?
| | Drugs, Generic | 1 | 2013 | 28 | 0.100 |
Why?
| | Bayes Theorem | 1 | 2015 | 421 | 0.100 |
Why?
| | Time-to-Treatment | 1 | 2015 | 251 | 0.090 |
Why?
| | Prevalence | 2 | 2020 | 2874 | 0.090 |
Why?
| | Adolescent | 7 | 2021 | 22573 | 0.090 |
Why?
| | Young Adult | 7 | 2021 | 14251 | 0.090 |
Why?
| | Epidemics | 1 | 2014 | 96 | 0.090 |
Why?
| | Colorado | 2 | 2019 | 4556 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2019 | 947 | 0.090 |
Why?
| | Aged, 80 and over | 5 | 2021 | 8346 | 0.090 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 605 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2014 | 208 | 0.090 |
Why?
| | Sex Work | 1 | 2011 | 23 | 0.090 |
Why?
| | Sexually Transmitted Diseases | 1 | 2014 | 168 | 0.090 |
Why?
| | Refugees | 1 | 2012 | 83 | 0.080 |
Why?
| | Models, Statistical | 1 | 2015 | 672 | 0.080 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 158 | 0.080 |
Why?
| | Computer Simulation | 1 | 2015 | 1003 | 0.080 |
Why?
| | Prospective Studies | 2 | 2022 | 8075 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1582 | 0.080 |
Why?
| | Drug Utilization | 1 | 2011 | 168 | 0.080 |
Why?
| | Criminal Law | 1 | 2010 | 31 | 0.080 |
Why?
| | Sexual Behavior | 1 | 2014 | 495 | 0.080 |
Why?
| | Homosexuality, Male | 1 | 2011 | 231 | 0.070 |
Why?
| | Regression Analysis | 1 | 2012 | 1001 | 0.070 |
Why?
| | Curriculum | 2 | 2024 | 1074 | 0.070 |
Why?
| | Insurance, Health | 1 | 2012 | 311 | 0.070 |
Why?
| | Time Factors | 2 | 2020 | 7133 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 2000 | 0.070 |
Why?
| | Texas | 2 | 2020 | 273 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1925 | 0.070 |
Why?
| | Patient Compliance | 1 | 2012 | 588 | 0.070 |
Why?
| | Minority Groups | 1 | 2009 | 285 | 0.060 |
Why?
| | Program Evaluation | 1 | 2011 | 944 | 0.060 |
Why?
| | Brain | 1 | 2019 | 2969 | 0.060 |
Why?
| | Risk Factors | 3 | 2020 | 10917 | 0.060 |
Why?
| | Family | 1 | 2010 | 685 | 0.060 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 58 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 134 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2014 | 2383 | 0.040 |
Why?
| | Forecasting | 2 | 2014 | 390 | 0.040 |
Why?
| | Assisted Living Facilities | 1 | 2021 | 20 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2021 | 90 | 0.040 |
Why?
| | Drug Approval | 1 | 2021 | 93 | 0.040 |
Why?
| | Particulate Matter | 1 | 2023 | 326 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 428 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 152 | 0.040 |
Why?
| | Off-Label Use | 1 | 2019 | 51 | 0.040 |
Why?
| | Oxazines | 1 | 2019 | 37 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 630 | 0.040 |
Why?
| | Vancomycin | 1 | 2019 | 95 | 0.040 |
Why?
| | India | 1 | 2019 | 213 | 0.030 |
Why?
| | Cohort Studies | 2 | 2019 | 6032 | 0.030 |
Why?
| | Risk-Taking | 1 | 2020 | 323 | 0.030 |
Why?
| | Pyridones | 1 | 2019 | 209 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2021 | 2064 | 0.030 |
Why?
| | Piperazines | 1 | 2019 | 375 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1043 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1378 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 757 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 733 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1812 | 0.030 |
Why?
| | Liberia | 1 | 2014 | 15 | 0.030 |
Why?
| | Endemic Diseases | 1 | 2014 | 33 | 0.030 |
Why?
| | Interinstitutional Relations | 1 | 2014 | 56 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2014 | 142 | 0.020 |
Why?
| | Length of Stay | 1 | 2019 | 1350 | 0.020 |
Why?
| | Cost Savings | 1 | 2013 | 86 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2933 | 0.020 |
Why?
| | Long-Term Care | 1 | 2014 | 118 | 0.020 |
Why?
| | Sex Distribution | 1 | 2014 | 388 | 0.020 |
Why?
| | Hospitalization | 1 | 2023 | 2460 | 0.020 |
Why?
| | Africa South of the Sahara | 1 | 2012 | 54 | 0.020 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 201 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2014 | 244 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2014 | 280 | 0.020 |
Why?
| | Appointments and Schedules | 1 | 2012 | 96 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 1154 | 0.020 |
Why?
| | Cost of Illness | 1 | 2014 | 324 | 0.020 |
Why?
| | Child, Preschool | 2 | 2019 | 11868 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2019 | 11793 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3634 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 463 | 0.020 |
Why?
| | Unsafe Sex | 1 | 2009 | 61 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 2139 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2014 | 610 | 0.020 |
Why?
| | Qualitative Research | 1 | 2015 | 1683 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 6464 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6085 | 0.010 |
Why?
| | Social Support | 1 | 2010 | 651 | 0.010 |
Why?
| | Child | 2 | 2019 | 22739 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2967 | 0.010 |
Why?
| | Risk Assessment | 1 | 2014 | 3752 | 0.010 |
Why?
| | Infant | 1 | 2019 | 10090 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1420 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2770 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3915 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 5922 | 0.010 |
Why?
|
|
Montague's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|